Analysts expect that Recro Pharma Inc (NASDAQ:REPH) will post earnings per share of ($0.67) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Recro Pharma’s earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.91). Recro Pharma reported earnings of ($0.48) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 39.6%. The firm is scheduled to issue its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.33). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.45) per share, with EPS estimates ranging from ($4.08) to ($0.10). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.72. The firm had revenue of $21.74 million for the quarter, compared to analyst estimates of $16.81 million. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%.
A number of institutional investors have recently bought and sold shares of REPH. Newtyn Management LLC acquired a new stake in Recro Pharma in the 2nd quarter valued at approximately $4,456,000. Engine Capital Management LP increased its holdings in Recro Pharma by 472.3% in the 2nd quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock valued at $1,964,000 after purchasing an additional 322,937 shares during the last quarter. Millennium Management LLC acquired a new stake in Recro Pharma in the 1st quarter valued at approximately $3,060,000. Sanders Morris Harris LLC acquired a new stake in Recro Pharma in the 2nd quarter valued at approximately $1,391,000. Finally, BlackRock Inc. increased its holdings in Recro Pharma by 27.6% in the 2nd quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock valued at $5,747,000 after purchasing an additional 247,559 shares during the last quarter. Hedge funds and other institutional investors own 55.03% of the company’s stock.
Shares of REPH stock traded down $0.38 during trading on Thursday, hitting $6.84. 173,742 shares of the stock traded hands, compared to its average volume of 260,378. The firm has a market cap of $149.79 million, a PE ratio of -3.44 and a beta of -0.82. The company has a debt-to-equity ratio of 2.22, a quick ratio of 1.42 and a current ratio of 1.59. Recro Pharma has a 52-week low of $4.78 and a 52-week high of $13.05.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.